Evidence map›Paper›PMID 32391396›Full record

ArticleERJ open research2020

Prognostic impact of pre-existing interstitial lung disease in non-HIV patients with

Shohei Hamada, Hidenori Ichiyasu, Megumi Inaba, Hiroshi Takahashi, Tomoki Sadamatsu, Kimitaka Akaike, Aiko Masunaga, Yasumasa Tashiro, Naomi Hirata, Takeshi Yoshinaga and 1 more

Open access · goldAbstract read
In one paragraph

Article in ERJ open research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Immunomodulatory treatment of interstitial lung disease.Therapeutic advances in respiratory disease
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Shohei HamadaDept of Respiratory Medicine, Kumamoto University Hospital, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.
Hidenori IchiyasuDept of Respiratory Medicine, Kumamoto University Hospital, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.
Megumi InabaDivision of Respiratory Medicine, Kumamoto Chuo Hospital, Kumamoto, Japan.
Hiroshi TakahashiDept of Respiratory Medicine, Kumamoto University Hospital, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.
Tomoki SadamatsuDept of Respiratory Medicine, Minamata City General Hospital and Medical Center, Minamata, Japan.
Kimitaka AkaikeDept of Respiratory Medicine, Kumamoto University Hospital, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.
Aiko MasunagaDept of Respiratory Medicine, Kumamoto University Hospital, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.
Yasumasa TashiroDept of Respiratory Medicine, Minamata City General Hospital and Medical Center, Minamata, Japan.
Naomi HirataDivision of Respiratory Medicine, Kumamoto Chuo Hospital, Kumamoto, Japan.
Takeshi YoshinagaDivision of Respiratory Medicine, Kumamoto Chuo Hospital, Kumamoto, Japan.
Takuro SakagamiDept of Respiratory Medicine, Kumamoto University Hospital, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.
Kumamoto University Hospital · JPSaiseikai Kumamoto Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe increasing incidence of life-threatening

methodsWe retrospectively reviewed the medical records of non-HIV PCP patients with (ILD group) or without (non-ILD group) pre-existing ILD. The clinical features and outcomes of the ILD group were compared with those of the non-ILD group. Cox regression models were constructed to identify prognostic factors.

results74 patients were enrolled in this study. The 90-day mortality was significantly higher in the ILD group than in the non-ILD group (62.5%

conclusionIn non-HIV PCP patients, pre-existing ILD is associated with a poorer prognosis. Prophylaxis for PCP is needed in patients with pre-existing ILD under immunosuppression.

Identifiers

PMID32391396
PMCPMC7196667
OpenAlexW3021996906

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.